Article
Oncology
Samuel J. Kerans, Santanu Samanta, Melissa A. L. Vyfhuis, Mariana Guerrero, Christine Ko Bang, Mark Mishra, Zaker Rana, Pradip P. Amin, Young Kwok, Michael J. Naslund, Jason K. Molitoris
Summary: Black men in the US have higher incidence and mortality rates of prostate cancer compared to non-Black men. However, this study found that Black patients treated with LDR brachytherapy achieved similar outcomes as non-Black patients, despite poorer socioeconomic status, suggesting a potential solution for reducing outcome disparities.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Emile Gogineni, Zaker Rana, Danielle Soberman, Baho Sidiqi, Vincent D'Andrea, Lucille Lee, Louis Potters, Bhupesh Parashar
Summary: The study found that both SBRT and LDR had similar rates of biochemical control and genitourinary toxicity at 5 years. However, SBRT had slightly higher gastrointestinal toxicity, while LDR had higher AUA and EPIC scores.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Manuel Behmueller, Nikolaos Tselis, Nikolaos Zamboglou, Eleni Zoga, Dimos Baltas, Claus Roedel, Georgios Chatzikonstantinou
Summary: The study evaluated the oncological outcome of high dose rate (HDR) brachytherapy (BRT) as monotherapy for clinically localised prostate cancer (PCA). The results showed long-term effectiveness and safety of HDR-BRT as a monotherapeutic treatment modality for low- and intermediate-risk PCA.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Brian J. Moran, Antony Koroulakis, Cristina Decesaris, Michelle H. Braccioforte, Neha Amin, Manuj Agarwal
Summary: This study compared the effects of I-125 and Cs-131 in prostate brachytherapy and found that short-term and long-term outcomes in terms of urinary, sexual, and bowel quality of life were similar. There was also no significant difference in biochemical relapse-free survival rate, supporting the continued use of Cs-131 as an effective and comparable alternative isotope.
Review
Medicine, Research & Experimental
Zhen Liang, Chen Yuliang, Ming Zhu, Yi Zhou, Xingcheng Wu, Hanzhong Li, Bu Fan, Zhien Zhou, Weigang Yan
Summary: This study compared the clinical outcomes of radical prostatectomy (RP) and low-dose-rate brachytherapy (LDR) for intermediate-risk prostate cancer (IRPC) patients. The results showed that LDR yielded improved biochemical recurrence-free survival (bRFS) compared to RP, with no significant differences in terms of clinical relapse-free survival (cRFS), cancer-specific survival (CSS), and overall survival (OS).
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Hideyasu Tsumura, Nobumichi Tanaka, Tomohiko Oguchi, Takuya Owari, Yasushi Nakai, Isao Asakawa, Kazuyoshi Iijima, Haruaki Kato, Iwao Hashida, Ken-ichi Tabata, Takefumi Satoh, Hiromichi Ishiyama
Summary: This study compared the clinical outcomes of seed brachytherapy alone and seed brachytherapy plus external-beam radiotherapy for intermediate-risk prostate cancer. The results showed that seed brachytherapy alone had a higher biochemical recurrence-free rate and fewer late toxicities.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Keisei Okamoto
Summary: The report discusses the importance of dose escalation for improved outcomes in intermediate-risk prostate cancer treatment, outlining a ten-step method for high-dose I-125 seed implantation monotherapy technique. Data shows that this method is reproducible and leads to excellent clinical outcomes in patients with intermediate-risk prostate cancer.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2021)
Article
Oncology
Jeff M. Michalski, Kathryn A. Winter, Bradley R. Prestidge, Martin G. Sanda, Mahul Amin, William S. Bice, Hiram A. Gay, Geoffrey S. Ibbott, Juanita M. Crook, Charles N. Catton, Adam Raben, Walter Bosch, David C. Beyer, Steven J. Frank, Michael A. Papagikos, Seth A. Rosenthal, H. Joseph Barthold, Mack Roach, Jennifer Moughan, Howard M. Sandler
Summary: The purpose of this study was to determine whether the addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer. The results showed that COMBO did not improve FFP compared to BT and caused greater toxicity. Therefore, BT can be considered as a standard treatment for men with intermediate-risk prostate cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Kanta Ka, Renaud Schiappa, Mario Terlizzi, Frederic Mallet, Etienne Martin, Marie -Eve Chand, Nicolas Demogeot, Didier Peiffert, Pascal Pommier, Magali Quivrin, Manon Kissel, Corentin Pasquier, Jonathan Khalifa, Alberto Bossi, Jean -Michel Hannoun-Levi, Pierre Blanchard
Summary: High dose-rate brachytherapy boost (HDR-BB) is an effective and tolerable adjuvant treatment for intermediate- and high-risk prostate cancer. This retrospective bicenter analysis of 709 patients showed a 5-year biochemical control rate of 87.5%, with potential for further improvement through combination with new hormonal agents or fractionation regimens.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Oncology
Tae Hyung Kim, Jason Joon Bock Lee, Jaeho Cho
Summary: Our study investigated the clinical features of PSA bounce in patients undergoing brachytherapy. PSA bounce is common and distinguishing between large bounces and biochemical failures is challenging. The results showed that age, the PSA nadir value at 2 years, and prostate volume were significant factors for PSA bounce.
Article
Oncology
Matthias Moll, Christopher Paschen, Alexandru Zaharie, Florian Berndl, Gregor Goldner
Summary: The study compared the efficacy and side effects of external beam radiotherapy (EBRT) and I-125 seeds brachytherapy in low-risk prostate cancer patients. Both treatments showed similar biochemical control rates, but differed in the prevalence of genitourinary and gastrointestinal side effects, with seeds showing higher genitourinary side effects and EBRT showing higher gastrointestinal side effects.
STRAHLENTHERAPIE UND ONKOLOGIE
(2021)
Article
Urology & Nephrology
Thenappan Chandrasekar, Nicholas Bowler, Adam Schneider, Hanan Goldberg, James R. Mark, Edouard J. Trabulsi, Costas D. Lallas, Leonard G. Gomella
Summary: The study found that patients with GG2, fIR, and uIR PCa treated with AS had significantly worse 5-year CSS and OS compared to those treated with AT. AS should not be the preferred treatment modality for IR PCa according to the analysis.
Article
Oncology
Hideyasu Tsumura, Nobumichi Tanaka, Tomohiko Oguchi, Takuya Owari, Yasushi Nakai, Isao Asakawa, Kazuyoshi Iijima, Haruaki Kato, Iwao Hashida, Ken-ichi Tabata, Takefumi Satoh, Hiromichi Ishiyama
Summary: For intermediate-risk prostate cancer patients, there is no significant difference in the biochemical recurrence (BCR)-free rates between seed brachytherapy (SEED-BT) and radical prostatectomy (RP). SEED-BT and RP can be adequately compared for oncological outcomes.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Yasir Alayed, Andrew Loblaw, Merrylee McGuffin, Hans T. Chung, Chia-Lin Tseng, Laura D'Alimonte, Patrick Cheung, Stanley Liu, William Chu, Ewa Szumacher, Joelle Helou, Ananth Ravi, Masoom Haider, Alexandre Mamedov, Liying Zhang, Gerard Morton
Summary: MRI-guided focal boost did not significantly improve local control for localized prostate cancer treated with single-fraction HDR monotherapy. Dosimetric parameters were not significant predictors of biochemical failure. Single-fraction HDR monotherapy should not be recommended outside of clinical trials.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Yat Man Tsang, Hannah Tharmalingam, Katherine Belessiotis-Richards, Shreya Armstrong, Peter Ostler, Robert Hughes, Roberto Alonzi, Peter J. Hoskin
Summary: This study compared biochemical control rates and toxicities in low-and intermediate risk prostate cancer patients treated with different radiation therapies. The 26 Gy/2 fractions HDR BT provided equivalent biochemical control with lower toxicity compared to 36.25 Gy/5 fractions SABR. Both 2-fraction HDR BT and 5-fraction SABR achieved better biochemical control rates than single dose 19 Gy HDR BT.
RADIOTHERAPY AND ONCOLOGY
(2021)